

Chandler E Gill

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6130299/publications.pdf>

Version: 2024-02-01

33
papers

566
citations

687220

13
h-index

642610

23
g-index

36
all docs

36
docs citations

36
times ranked

539
citing authors

#	ARTICLE	IF	CITATIONS
1	Subthalamic nucleus deep brain stimulation in early stage Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 731-737.	1.1	112
2	Comparison of Botulinum Neurotoxin Preparations for the Treatment of Cervical Dystonia. <i>Clinical Therapeutics</i> , 2007, 29, 1325-1337.	1.1	84
3	Botulinum toxin type A therapy during pregnancy. <i>Movement Disorders</i> , 2004, 19, 1384-1385.	2.2	65
4	Is deep brain stimulation neuroprotective if applied early in the course of PD?. <i>Nature Clinical Practice Neurology</i> , 2008, 4, 424-426.	2.7	43
5	Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs. <i>Parkinsonism and Related Disorders</i> , 2004, 10, 475-479.	1.1	40
6	Clinical Features of Tourette Syndrome. <i>Journal of Child Neurology</i> , 2020, 35, 166-174.	0.7	27
7	Neuropsychological Effects of Deep Brain Stimulation in Subjects with Early Stage Parkinson's Disease in a Randomized Clinical Trial. <i>Journal of Parkinson's Disease</i> , 2015, 5, 151-163.	1.5	25
8	Pilot Study Assessing the Feasibility of Applying Bilateral Subthalamic Nucleus Deep Brain Stimulation in Very Early Stage Parkinson's Disease: Study Design and Rationale. <i>Journal of Parkinson's Disease</i> , 2012, 2, 215-223.	1.5	18
9	Methods for Surgical Targeting of the STN in Early-Stage Parkinson's Disease. <i>Frontiers in Neurology</i> , 2014, 5, 25.	1.1	17
10	Top of the Basilar Syndrome Presenting With Convulsions. <i>JAMA Neurology</i> , 2017, 74, 248.	4.5	15
11	Neurological Complications of Therapeutic Monoclonal Antibodies: Trends from Oncology to Rheumatology. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 75.	2.0	15
12	Continuation of Long-Term Care for Cervical Dystonia at an Academic Movement Disorders Clinic. <i>Toxins</i> , 2013, 5, 776-783.	1.5	13
13	Potential subjects' responses to an ethics questionnaire in a phase I study of deep brain stimulation in early Parkinson's disease. <i>Journal of Clinical Ethics</i> , 2012, 23, 207-16.	0.1	13
14	Spasticity treatment facilitates direct care delivery for adults with profound intellectual disability. <i>Movement Disorders</i> , 2010, 25, 466-473.	2.2	12
15	Deep Brain Stimulation for Early-Stage Parkinson's Disease: An Illustrative Case. <i>Neuromodulation</i> , 2011, 14, 515-522.	0.4	9
16	Barriers to Conducting Research With Community-Dwelling Adults Who Have Intellectual Disabilities. <i>Intellectual and Developmental Disabilities</i> , 2011, 49, 392-396.	0.6	9
17	Prevalence of Spasticity in Nursing Home Residents. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 1157-1160.	1.2	8
18	Difficulty in securing treatment for degenerative hip disease in a patient with Down syndrome: the gap remains open. <i>Journal of the National Medical Association</i> , 2006, 98, 93-6.	0.6	7

#	ARTICLE	IF	CITATIONS
19	Deep brain stimulation for Parkinson's disease: the Vanderbilt University Medical Center experience, 1998-2004. Tennessee Medicine: Journal of the Tennessee Medical Association, 2007, 100, 45-7.	0.1	7
20	NEUROTOXIN INJECTION FOR MOVEMENT DISORDERS. CONTINUUM Lifelong Learning in Neurology, 2010, 16, 131-157.	0.4	5
21	Depression and intelligence in patients with Parkinson's disease and deep-brain stimulation. Journal of the National Medical Association, 2006, 98, 1121-5.	0.6	4
22	Discordance in Informed Consent Response on the Basis of Demographic Factors: Brief Report. Intellectual and Developmental Disabilities, 2010, 48, 175-179.	0.6	3
23	A pilot trial of onabotulinumtoxinA for the treatment of cervicothoracic myofascial pain. Botulinum Journal, 2011, 2, 6.	0.2	3
24	Postseizure aphasia in Wernicke's encephalopathy: a case report and review of literature. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 2593-2598.	1.0	3
25	Poster 100: Prevalence and Impact of Spasticity in a Single Nursing Home. Archives of Physical Medicine and Rehabilitation, 2008, 89, e52.	0.5	2
26	Mystery Case: Diagnostic challenges in a young patient with hypereosinophilia. Neurology, 2017, 89, e159-e165.	1.5	2
27	A New Pathologic KMT2B Variant Associated with Childhood Onset Dystonia Presenting as Variable Phenotypes among Family Members. Tremor and Other Hyperkinetic Movements, 2022, 12, 7.	1.1	2
28	Successful treatment of childhood spasticity secondary to cerebral palsy using Botox. Tennessee Medicine: Journal of the Tennessee Medical Association, 2003, 96, 511-3.	0.1	1
29	Reply: Botulinum type A therapy during pregnancy. Movement Disorders, 2005, 20, 1082-1082.	2.2	0
30	Lengthened duration of benefit from botulinum toxin injections for the treatment of spasticity. Botulinum Journal, 2008, 1, 199.	0.2	0
31	Long-Term Care Resident Awareness and Interest in Spasticity Treatments. Geriatrics (Switzerland), 2021, 6, 21.	0.6	0
32	OnabotulinumtoxinA: BOTOXÂ®. , 2012, , 436-451.		0
33	Combined treatment with BTX-A and ITB for spasticity: case report. Tennessee Medicine: Journal of the Tennessee Medical Association, 2007, 100, 41-2, 44.	0.1	0